Latest Health News

Page 11 of 271
Talius Group returned to positive operating cash flow in the September quarter as revenue, subscriptions and annualised recurring revenue all increased. The next test is converting newly contracted work into active deployments, recurring revenue and cash receipts.
Victor Sage
Victor Sage
15 Oct 2026
Treasury Wine Estates has reiterated its FY27 earnings guidance after a bruising year marked by a $1.1 billion statutory loss, a suspended dividend and a major US reset. Early trading indicators are improving, but the recovery now depends on execution across costs, inventory, supply and the Americas review.
Victor Sage
Victor Sage
15 Oct 2026
Elixinol Wellness lifted Q3 gross profit 27% and delivered a fourth consecutive quarter of positive underlying operating cash flow, despite statutory operating cash flow remaining negative and cash below A$1 million. The proposed all-scrip Vitable acquisition could add scale, but shareholder approval and a thin liquidity buffer remain important next tests.
Victor Sage
Victor Sage
14 Oct 2026
InteliCare Holdings Limited (ASX:ICR) used FY2026 to move from pilot projects into contracted deployment, led by an estimated $8.8 million five-year agreement with mecwacare. Revenue and customer receipts more than doubled, although the company remains loss-making and reliant on disciplined rollout execution and further funding.
Victor Sage
Victor Sage
13 Oct 2026
Elixinol Wellness has lifted combined hemp sales 12% to $6.41 million in the first nine months of 2026, while unaudited gross profit rose 41%. Two major grocery programs are now fully supplied through 2027, with Hemp Gold Protein due back at Costco in Australia and New Zealand.
Victor Sage
Victor Sage
13 Oct 2026
PainChek has expanded its Sabra relationship from two initial facilities to 23 US communities across five operators, covering 808 contracted memory care licences. The immediate test is whether those contracts become implemented recurring revenue by the end of 2026.
Victor Sage
Victor Sage
13 Oct 2026
Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.
Ada Torres
Ada Torres
13 Oct 2026
Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.
Ada Torres
Ada Torres
12 Oct 2026
AXP Energy has launched a 1-for-1 non-renounceable entitlement offer seeking between A$1.2 million and A$2.249 million. The funding could support Oklahoma development, but the prospectus also highlights material going-concern uncertainty, creditor dependence and significant dilution for shareholders who do not participate.
Victor Sage
Victor Sage
12 Oct 2026
Southern Cross Electrical Engineering will acquire Victorian fire and HVAC services group Entire Operations for up to $112.1 million, funded from existing cash reserves. The deal adds mechanical services, expands SCEE’s national fire platform and lifts FY27 EBITDA guidance to at least $110 million.
Victor Sage
Victor Sage
12 Oct 2026
Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.
Victor Sage
Victor Sage
9 Oct 2026
Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
Ada Torres
9 Oct 2026

Browse the archive

Full archive